Can-Fite BioPharma Ltd.
CANF
$0.53
-$0.04-6.81%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 2.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 2.25% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 2.25% |
| SG&A Expenses | -- | -- | -- | -- | -2.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -- | -9.93% |
| Operating Income | -- | -- | -- | -- | 10.72% |
| Income Before Tax | -- | -- | -- | -- | 7.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -- | 7.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -- | 7.07% |
| EBIT | -- | -- | -- | -- | 10.72% |
| EBITDA | -- | -- | -- | -- | 10.74% |
| EPS Basic | -- | -- | -- | -- | 21.58% |
| Normalized Basic EPS | -- | -- | -- | -- | 41.73% |
| EPS Diluted | -- | -- | -- | -- | 21.58% |
| Normalized Diluted EPS | -- | -- | -- | -- | 41.73% |
| Average Basic Shares Outstanding | -- | -- | -- | -- | 54.71% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | 54.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |